These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 17785018)
41. Electrocardiographic changes in HIV-infected, drug experienced patients treated with atazanavir. Mahnke L; Child M; Satin L; Persson A; Bertz R; Lawrence J AIDS; 2008 Aug; 22(13):1698. PubMed ID: 18670241 [No Abstract] [Full Text] [Related]
42. Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy. Young J; Glass TR; Bernasconi E; Rickenbach M; Furrer H; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC; J Clin Epidemiol; 2009 Jun; 62(6):632-41. PubMed ID: 19108985 [TBL] [Abstract][Full Text] [Related]
43. Drug interactions. Atazanavir and acid-reducing agents. TreatmentUpdate; 2006; 18(3):4. PubMed ID: 17209238 [No Abstract] [Full Text] [Related]
44. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure. Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448 [TBL] [Abstract][Full Text] [Related]
45. Atazanavir-induced urine crystals demonstrated by infrared spectroscopic analysis. Inagaki I; Adachi M; Ito H; Yasuda M; Tsurumi H; Deguchi T; Seishima M Urol Int; 2015; 94(1):121-4. PubMed ID: 24334974 [TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924 [TBL] [Abstract][Full Text] [Related]
47. FDA notifications. Alternative dosing regimen for atazanavir is approved. AIDS Alert; 2008 Nov; 23(11):129-30. PubMed ID: 19048649 [No Abstract] [Full Text] [Related]
48. FDA notifications. Revised atazanavir package insert. AIDS Alert; 2008 Mar; 23(3):35-6. PubMed ID: 18661642 [No Abstract] [Full Text] [Related]
49. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Brewster UC; Perazella MA Am J Kidney Dis; 2004 Nov; 44(5):e81-4. PubMed ID: 15492941 [TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study. Martin DE; Galbraith H; Schettler J; Ellis C; Doto J Clin Ther; 2008 Oct; 30(10):1794-805. PubMed ID: 19014835 [TBL] [Abstract][Full Text] [Related]
51. Hypermenorrhea associated with ritonavir. Nielsen H Lancet; 1999 Mar; 353(9155):811-2. PubMed ID: 10459969 [No Abstract] [Full Text] [Related]
52. Acute renal failure due to bilateral ureteral stone impaction in an HIV-positive patient. Moriyama Y; Minamidate Y; Yasuda M; Ehara H; Kikuchi M; Tsuchiya T; Deguchi T; Tsurumi H Urol Res; 2008 Oct; 36(5):275-7. PubMed ID: 18633605 [TBL] [Abstract][Full Text] [Related]
53. Elevated alkaline phosphatase with raltegravir in a treatment experienced HIV patient. Fleischbein E; O'Brien J; Martelino R; Fenstersheib M AIDS; 2008 Nov; 22(17):2404-5. PubMed ID: 18981785 [No Abstract] [Full Text] [Related]
54. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. Ripamonti D; Cattaneo D; Maggiolo F; Airoldi M; Frigerio L; Bertuletti P; Ruggeri M; Suter F AIDS; 2007 Nov; 21(18):2409-15. PubMed ID: 18025877 [TBL] [Abstract][Full Text] [Related]